Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma Document date: 2018_8_30
ID: uzge50xu_19
Snippet: Within group analyses of ACD at multiple time points during the entire study period (−2 to 12 weeks) were compared using 2-way ANOVA, followed by Sidak's multiple comparisons test. This was only done for the BIS and MONT groups. Between-group analyses of ACD (BIS versus MONT groups) were done using the Wilcoxon matched-pairs signed rank test. Within group analyses of treatment effect comparing "Pre" (measured during run-in period −2 to 0 week.....
Document: Within group analyses of ACD at multiple time points during the entire study period (−2 to 12 weeks) were compared using 2-way ANOVA, followed by Sidak's multiple comparisons test. This was only done for the BIS and MONT groups. Between-group analyses of ACD (BIS versus MONT groups) were done using the Wilcoxon matched-pairs signed rank test. Within group analyses of treatment effect comparing "Pre" (measured during run-in period −2 to 0 week) and "Post" (measured at 12 weeks) measurements of changes in sEDN for all 3 groups (BIS, MONT and OBS) were done using the Wilcoxon matched-pairs signed rank test. Each group was then subgrouped according to presence or absence of any virus and change in sEDN with treatment from "Pre" to "Post" was analyzed using the same statistical test. Rescue medication usage within each group (BIS and MONT) and between each group were also compared. Data that were normally distributed were presented as mean values, unless otherwise noted. P values < 0.05 were considered statistically significant. Fig. 2 .
Search related documents:
Co phrase search for related documents- absence presence and time point: 1, 2, 3, 4, 5, 6
- absence presence and treatment effect: 1, 2, 3, 4, 5, 6, 7, 8, 9
- absence presence and virus absence presence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ANOVA compare and time point: 1, 2
- ANOVA compare and treatment effect: 1
- entire study period and study period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- group analysis and study period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- group analysis and time point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- group analysis and treatment effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- mean value and study period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- mean value and time point: 1, 2, 3, 4, 5, 6, 7, 8
- mean value present and study period: 1
- MONT BIS group and study period: 1, 2, 3
- MONT BIS group and time point: 1, 2, 3
- MONT BIS group rescue medication usage and study period: 1
- MONT BIS group rescue medication usage and time point: 1
- mont group and study period: 1, 2, 3
- mont group and time point: 1, 2, 3
- multiple comparison and study period: 1
Co phrase search for related documents, hyperlinks ordered by date